Johnson & Johnson Edges Out Procter & Gamble for Long-Term Dividend Growth

Johnson & Johnson (NYSE: JNJ) and Procter & Gamble (NYSE: PG) are both Dividend Kings with strong track records, but which one is the better choice for a 20-year investment? The answer depends on three key factors: dividend coverage, business durability, and structural risk.

Procter & Gamble has a longer dividend increase streak of 70 consecutive years compared to Johnson & Johnson’s 64. However, Johnson & Johnson has better dividend coverage, using about 46% of its adjusted EPS guidance for dividends, while Procter & Gamble uses about 62%. Johnson & Johnson also expects free cash flow to approach $21 billion in 2026, providing more room for future dividend increases.

Procter & Gamble wins on business durability, as its products like Tide, Pampers, and Charmin are essential in any economy. Johnson & Johnson, on the other hand, faces legal challenges that impact its financial results. In Q1 2026, net income fell 52.4% due to litigation charges.

Structural risk favors Johnson & Johnson, as Procter & Gamble struggles with flat organic sales and cost pressures. Johnson & Johnson’s growth in other areas, such as Tremfya sales, helps offset declines in drugs like Stelara. Over the past decade, Johnson & Johnson’s share price rose 180.5%, compared to Procter & Gamble’s 116.7%. Management aims for double-digit growth by the end of the decade, giving Johnson & Johnson an edge for long-term dividend growth.